JLK, the first domestic medical AI company listed on KOSDAQ, has undertaken a renaming initiative to expand the supply of its stroke AI solutions in medical settings.
Medical AI specialist JLK (CEO Dongmin Kim) announced on the 18th that it will change the names of its 11 comprehensive stroke AI diagnostic solutions?the largest number worldwide?to enhance convenience in medical environments and actively secure a leading position in the medical AI market.
The JLK solutions, previously known as the JBS series, will all be renamed under the JLK brand through this rebranding. The solution numbers, formerly subtitled as 01K to 10K, will be replaced with medical terms familiar to stroke healthcare professionals such as DWI, LVO, and CTP to improve usability in clinical practice.
The company stated that this rebranding aims to establish a more familiar AI solution presence among medical staff. Additionally, by providing precise diagnostic information through cutting-edge AI technology, the solutions will introduce new biomarkers for the previously challenging stroke diagnosis, thereby contributing to improved treatment quality and prognosis for stroke patients.
The new naming includes a total of 11 types: ▲JLK-DWI ▲JLK-PWI ▲JLK-WMH ▲JLK-CMB ▲JLK-LAC ▲JLK-UIA ▲JLK-LVO ▲JLK-ICH ▲JLK-CTL ▲JLK-CTI ▲JLK-CTP.
JLK CEO Dongmin Kim said, "This renaming was carried out with a focus on convenience in medical settings," adding, "We expect it to serve as an opportunity for doctors to recognize JLK’s AI solutions more intuitively."
He also stated, “Rapid AI solution selection and quick diagnosis are expected to contribute to better prognoses for stroke patients,” and added, “Stroke AI solutions are already known as essential elements for precise diagnosis and efficient patient management, and we predict that most hospitals will decide to adopt them within this year.”
Last year, JLK successfully entered the domestic non-reimbursed fee market with JLK-DWI (formerly JBS-01K), and has already supplied stroke diagnostic AI solutions to over 200 hospital sites, generating revenue. The company expects significant sales growth due to increased utilization in neurology, neurosurgery, radiology, emergency medicine, and rehabilitation medicine departments, as well as rising adoption in both large domestic hospitals and small to medium-sized hospitals equipped with CT and MRI devices. The goal is to capture 85% of the domestic hospital market by 2026.
Meanwhile, JLK plans to enter the U.S. Food and Drug Administration (FDA) non-reimbursed market this year, which is several times larger than the domestic non-reimbursed market, to actively generate revenue.
© The Asia Business Daily(www.asiae.co.kr). All rights reserved.
